Israel's Teva Pharmaceuticals will get exclusive marketing rights in the U.S. and Canada to Andrx's line of generic oral contraceptive products now awaiting regulatory approval. Financial terms were not disclosed, but analysts said the deal fills holes in Teva's product line and Andrx gets Teva's marketing channels.

Related Summaries